Sign In
Buy IGC
$0.300
+0.0100 (+3.45%)
At Close: Jun 03, 2026
IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024
07:00am, Wednesday, 20'th Mar 2024
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024.
IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer's Pipeline
03:00pm, Tuesday, 12'th Mar 2024
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma (IGC)- Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer's Pipeline.
IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target
12:01pm, Friday, 23'rd Feb 2024
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Ascendiant Coverage.
IGC Pharma Reports Third Quarter Fiscal 2024 Results
07:05pm, Friday, 16'th Feb 2024
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Reports Third Quarter Fiscal 2024 Results.
IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model
09:20am, Thursday, 01'st Feb 2024
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--TGR-63 Reduces Agitation in Alzheimer's Mouse Model.
IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer's
09:20am, Tuesday, 23'rd Jan 2024
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Breakthrough - Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer's.
IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer's Trial
09:20am, Wednesday, 17'th Jan 2024
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer's Trial.
Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer's
09:20am, Tuesday, 19'th Dec 2023
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer's.
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024.
IGC Pharma Announces Collaboration to Integrate AI into Clinical Trials
08:30am, Wednesday, 06'th Dec 2023
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American: IGC) today announced an Artificial Intelligence (AI) collaboration with Los Andes University's Center for
IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives
08:30am, Tuesday, 21'st Nov 2023
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives.
IGC Pharma Reports Second Quarter Fiscal 2024 Results
08:00am, Monday, 13'th Nov 2023
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Reports Second Quarter Fiscal 2024 Results.
IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy
03:30pm, Thursday, 19'th Oct 2023
POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy.
POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer's Candidate.
IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto Rico
08:30am, Wednesday, 02'nd Aug 2023
POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto Rico.
